DBV Technologies Q2 2026: Cash Burn Accelerates as BLA Submission Slips to Q3
DBVT sits 75% above its 52-week low of $8.51.
Summary
DBV Technologies' Q2 2026 10-Q shows accelerating cash burn, a delayed BLA submission, and a shrinking cash balance, offset by progress in clinical trials and commercial readiness.
Key Events · Earnings and Guidance · DBVT
-
Net Loss Widens
Net loss of $98.0 million for H1 2026, up from $69.0 million in H1 2025, driven by a 43% increase in operating expenses to $100.1 million.
-
Cash Burn Accelerates
Cash and equivalents fell to $174.9 million at June 30, 2026, from $194.2 million at year-end 2025. Management projects runway into Q3 2027.
-
BLA Submission Delayed
The BLA submission for VIASKIN Peanut patch in children aged 4-7 years has been pushed to Q3 2026, citing FDA feedback on data organization and formatting.
-
Clinical and Commercial Progress
Initiated Phase 2 THRIVE study in infants aged 6-12 months. Signed letters of intent with Fareva Amboise for commercial manufacturing and ICS for U.S. distribution.
Analysis · DBVT · Life Sciences
A sharp rise in operating expenses to $100.1 million drove DBV Technologies' net loss to $98.0 million for the first half of 2026, nearly double the prior-year period. Cash and equivalents fell to $174.9 million from $194.2 million at year-end 2025, though management asserts runway into Q3 2027. The BLA submission for VIASKIN Peanut in children aged 4-7 has been delayed to Q3 2026, adding execution risk. On the positive side, the company initiated the Phase 2 THRIVE study in infants and signed letters of intent for commercial manufacturing and distribution, signaling launch preparedness. A French tax audit covering 2022-2025 adds a layer of regulatory uncertainty.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 29.2% of the 1713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DBVT was trading at $14.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $937.9M. The 52-week trading range was $8.51 to $26.19. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.